Apyx Medical (NASDAQ: APYX) CEO awarded 213,948 stock options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Apyx Medical Corp disclosed that Chief Executive Officer Charles D. Goodwin II received a grant of stock options for 213,948 shares of common stock. The options have an exercise price of $4.65 per share, vest ratably over 36 months, and become fully exercisable on the third anniversary of the grant date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Goodwin Charles D. II

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Option to Buy)	213,948	$0.00	--

Holdings After Transaction: Stock Option (Option to Buy) — 213,948 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Stock options granted: 213,948 options Exercise price: $4.65 per share Underlying shares: 213,948 shares +3 more

6 metrics

Stock options granted 213,948 options Grant to CEO on June 11, 2026

Exercise price $4.65 per share Stock option strike price

Underlying shares 213,948 shares Common stock subject to options

Expiration date June 11, 2036 Option term end

Vesting period 36 months Ratable vesting until third anniversary

Options held after grant 213,948 options Total derivative securities following transaction

Key Terms

Stock Option (Option to Buy), Common Stock, exercise price, vesting, +1 more

5 terms

Stock Option (Option to Buy) financial

"security_title: Stock Option (Option to Buy)"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

exercise price financial

"conversion_or_exercise_price: 4.6500"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shall vest ratably over a thirty six (36) month period"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

derivative securities financial

"derivativeTransactionCount: 1"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/15/2026 - 07:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Goodwin Charles D. II

(Last)

(First)

(Middle)

C/O APYX MEDICAL CORPORATION

5115 ULMERTON ROAD

(Street)

CLEARWATER

FLORIDA

33760

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Apyx Medical Corp [ APYX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Option to Buy)	$4.65	06/11/2026		A		213,948		⁽¹⁾	06/11/2036	Common Stock	213,948	$0	213,948	D

Explanation of Responses:

1. Reporting person was granted a stock option which shall vest ratably over a thirty six (36) month period and shall become fully vested and fully exercisable on the third anniversary of the date of grant.

	/s/ Charles D. Goodwin, II	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Apyx Medical (APYX) report in this Form 4 filing?

Apyx Medical reported that CEO Charles D. Goodwin II received a grant of 213,948 stock options. These options relate to common stock and are a derivative security with a defined vesting schedule and exercise terms.

How many stock options did the Apyx Medical (APYX) CEO receive?

The CEO received 213,948 stock options. Each option represents the right to buy one share of Apyx Medical common stock, subject to vesting over time and payment of the stated exercise price when exercised.

What is the exercise price and expiration date of the APYX CEO’s options?

The stock options have an exercise price of $4.65 per share and expire on June 11, 2036. The CEO can exercise vested options any time before this expiration date, subject to company and plan rules.

How do the Apyx Medical (APYX) CEO’s options vest over time?

The options vest ratably over a 36‑month period and become fully vested and exercisable on the third anniversary of the grant date. This means portions vest monthly or periodically until full vesting after three years.

How many derivative securities does the APYX CEO hold after this grant?

After this grant, the CEO holds 213,948 stock options as reported in the filing. This figure reflects the total derivative securities following the transaction, all tied to Apyx Medical’s common stock under the option award.

Is this Apyx Medical (APYX) Form 4 an open‑market stock purchase or sale?

No, the Form 4 reflects a grant of stock options to the CEO, not an open‑market purchase or sale. The transaction is coded as a grant or award acquisition with no price paid at the time of grant.